CL2020002369A1 - Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina - Google Patents

Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina

Info

Publication number
CL2020002369A1
CL2020002369A1 CL2020002369A CL2020002369A CL2020002369A1 CL 2020002369 A1 CL2020002369 A1 CL 2020002369A1 CL 2020002369 A CL2020002369 A CL 2020002369A CL 2020002369 A CL2020002369 A CL 2020002369A CL 2020002369 A1 CL2020002369 A1 CL 2020002369A1
Authority
CL
Chile
Prior art keywords
lactalbumin
pharmaceutical
alpha
food
food supplement
Prior art date
Application number
CL2020002369A
Other languages
English (en)
Inventor
Paolo Mainardi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002369A1 publication Critical patent/CL2020002369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparación farmacéutica o de complemento alimenticio que incluye alfa-lactoalbúmina y al menos un ácido graso de cadena corta (SCFA) o un precursor o derivado del mismo para uso en el tratamiento de trastornos del sistema nervioso central; el SCFA o su precursor o derivado puede estar contenido en al menos una primera unidad de dosificación junto con un portador aceptable desde el punto de vista farmacéutico o alimentario y la alfa-lactoalbúmina en al menos una segunda unidad de dosificación junto con un portador aceptable desde el punto de vista farmacéutico o alimentario, y dichas unidades de dosificación pueden ser unidades distintas pretendidas para administración simultánea o separada o la preparación puede consistir en una composición farmacéutica o de complemento alimenticio que comprende dicho al menos un ácido graso de cadena corta o un precursor o derivado del mismo y alfa- lactoalbúmina juntos con un portador aceptable desde el punto de vista farmacéutico o alimentario.
CL2020002369A 2018-03-14 2020-09-14 Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina CL2020002369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000003557A IT201800003557A1 (it) 2018-03-14 2018-03-14 Preparazione farmaceutica o di integratore alimentare a base di alfa-lattoalbumina

Publications (1)

Publication Number Publication Date
CL2020002369A1 true CL2020002369A1 (es) 2021-05-07

Family

ID=62455774

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002369A CL2020002369A1 (es) 2018-03-14 2020-09-14 Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina

Country Status (21)

Country Link
US (1) US11554162B2 (es)
EP (1) EP3764992B1 (es)
JP (1) JP7372269B2 (es)
AU (1) AU2019233637B2 (es)
BR (1) BR112020018533A2 (es)
CA (1) CA3093505A1 (es)
CL (1) CL2020002369A1 (es)
DK (1) DK3764992T3 (es)
EA (1) EA202092105A1 (es)
ES (1) ES2992560T3 (es)
FI (1) FI3764992T3 (es)
HR (1) HRP20241413T1 (es)
HU (1) HUE068746T2 (es)
IT (1) IT201800003557A1 (es)
LT (1) LT3764992T (es)
MX (1) MX2020009470A (es)
PT (1) PT3764992T (es)
RS (1) RS66128B1 (es)
SI (1) SI3764992T1 (es)
SM (1) SMT202400448T1 (es)
WO (1) WO2019175274A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243633A1 (en) * 2020-11-13 2023-09-20 Sila S.P.A. Orally dispersible compound containing an ester or salt of n-butyric acid and process for production
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096870A (en) * 1994-01-05 2000-08-01 Sepragen Corporation Sequential separation of whey
US6884421B2 (en) * 2002-03-27 2005-04-26 Council Of Scientific And Industrial Research Pharmaceutical composition for diabetic nephropathy
JP2006219458A (ja) 2005-02-14 2006-08-24 Meiji Milk Prod Co Ltd 虚血性腸疾患抑制剤
CN101677953A (zh) * 2007-02-21 2010-03-24 纸型电池有限公司 用于离子电渗疗法的特比萘芬制剂
WO2008138348A1 (en) * 2007-05-09 2008-11-20 Nya Hamlet Pharma Ab Preparation of complexed lactalbumin
IT1392333B1 (it) * 2008-12-16 2012-02-28 Giofarma S R L Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa
JP5409808B2 (ja) 2010-07-02 2014-02-05 森永乳業株式会社 治療薬および治療方法
CN105746711A (zh) * 2014-12-15 2016-07-13 内蒙古蒙牛乳业（集团）股份有限公司 一种改善睡眠的牛奶制品及其制备方法
MX2018005651A (es) 2015-11-09 2018-08-01 Mjn Us Holdings Llc Composiciones nutritivas que comprenden lactobacillus rhamnosus gg, asi como butirato de la dieta y/o un compuesto para estimular la formacion de butirato endogeno.

Also Published As

Publication number Publication date
JP2021517591A (ja) 2021-07-26
ES2992560T3 (es) 2024-12-13
SI3764992T1 (sl) 2025-05-30
SMT202400448T1 (it) 2024-11-15
PT3764992T (pt) 2024-10-21
RS66128B1 (sr) 2024-11-29
US20210361748A1 (en) 2021-11-25
AU2019233637A1 (en) 2020-10-22
EP3764992A1 (en) 2021-01-20
DK3764992T3 (da) 2024-10-07
EA202092105A1 (ru) 2021-02-20
MX2020009470A (es) 2022-11-03
HUE068746T2 (hu) 2025-01-28
EP3764992B1 (en) 2024-08-14
WO2019175274A1 (en) 2019-09-19
LT3764992T (lt) 2024-12-10
BR112020018533A2 (pt) 2020-12-29
IT201800003557A1 (it) 2019-09-14
CA3093505A1 (en) 2019-09-19
US11554162B2 (en) 2023-01-17
FI3764992T3 (fi) 2024-10-29
JP7372269B2 (ja) 2023-10-31
AU2019233637B2 (en) 2024-08-15
HRP20241413T1 (hr) 2024-12-20

Similar Documents

Publication Publication Date Title
MX2021004999A (es) Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos.
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
WO2016138030A3 (en) Compositions and methods for tolerizing the immune system to allergens
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
EP4512394A3 (en) Dosage forms and use thereof
CR7654A (es) Una combinacion de azelatina y esteroides
ES2659353T3 (es) Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer
BR112015022306A2 (pt) adoçante aperfeiçoado
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
MX2019001318A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos
AR110344A1 (es) Métodos y regímenes de alimentación que comprenden la administración de composiciones nutricionales que contienen butirato dietario
MX2019011270A (es) Productos masticables en gel para ingredientes farmaceuticos activos.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
EA202092105A1 (ru) Фармацевтический состав или состав пищевой добавки на основе альфа-лактальбумина
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
PH12018000227B1 (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
WO2017152130A8 (en) Pharmaceutical compositions
MX2021000282A (es) Composicion que contiene un 7beta-hidroxicolesterol y un vehiculo de lipido, y su uso en el tratamiento de patologias neoplasicas.
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
AR030635A1 (es) Uso de arginina en la preparacion de un medicamento para la prevencion y el tratamiento de los efectos colaterales asociados con la administracion endovenosa de productos farmaceuticos